Advertisement

Prodrugs pp 1377-1386 | Cite as

Case Study: Valganciclovir: A Prodrug of Ganciclovir

  • Hans Maag
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume V)

Abstract

Valganciclovir (Valcyte™) is the commercially successful example of a number of prodrugs investigated to improve the oral bioavailability of ganciclovir (Cytovene®), a potent antiviral agent for the treatment of cytomegalovirus (CMV) infections (Markham and Faulds, 1994). Ganciclovir is a fairly polar compound (logP = −1.65) limiting its uptake by passive routes and has moderate solubility in water at pH 7 (6 mg/mL at 37°C). Ganciclovir is supplied in two formulations: a) a intravenous formulation (IV) in the form of a lyophilized powder of the sodium salt to be reconstituted with water and b) a oral tablet formulation (Physician’s Desk Reference 2004). The IV formulation is quite basic and has to be administered slowly in dilute form. The oral formulation is adversely impacted by the physical properties of the compound, resulting in an oral bioavailability of approximately 7%. Therefore, the oral formulation is used mainly for maintenance therapy, while for induction therapy, IV formulations are being used to assure adequate exposure levels.

Keywords

Amino Acid Ester Ester Prodrug Diastereomeric Mixture Good Oral Bioavailability Passive Route 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Brown F, Banken L, Saywell K, and Arum I, Pharmacokinetics of Valganciclovir and Ganciclovir Following Multiple Oral Dosages of Valganciclovir in HIV-and CMV-Seropositive Volunteers. Clin Pharmacokinet 1999; 37:167–176PubMedCrossRefGoogle Scholar
  2. Czock D, Scholle C, Rasche FM, Schaarschmidt D, and Keller F, Pharmacokinetics of Valganciclovir and Ganciclovir in Renal Impairment. Clin Pharm Therap 2002; 72:142–150PubMedCrossRefGoogle Scholar
  3. Ho WB, 1995 unpublished, personal communicationGoogle Scholar
  4. Kim I, Chu XY, Kim S, Provoda CJ, Lee KD, and Amidon GL, Identification of a Human Valacyclovirase. J Biol Chem 2003; 278:25348–25356PubMedCrossRefGoogle Scholar
  5. Markham A, and Faulds D, Ganciclovir. Drugs 1994; 48; 455–484PubMedCrossRefGoogle Scholar
  6. Martin DF, Sierra-Madero J, Walmsley S, Wolitz RA, Macey K, Georgiou P, Robinson CA, and Stempien MJ, A Controlled Trial of Valganciclovir as Induction Therapy for Cytomegalovirus Retinitis. N Engl J Med 2002; 346:1119–1126PubMedCrossRefGoogle Scholar
  7. Martin JC., Tippie MA, McGee DPC, and Verheyden JPH, Synthesis and Antiviral Activity of Various Esters of 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine. J Pharm Sci 1987; 76:180–184PubMedCrossRefGoogle Scholar
  8. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, and Pescovitz MD on behalf of the Valganciclovir Solid Organ Transplant Group, Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients. Am J Transplant 2004; 4:611–620PubMedCrossRefGoogle Scholar
  9. Physician’s Desk Reference, 58th Edition Published by Thomson PDR Montvale NJ 07645, 2004, 2894Google Scholar
  10. Physician’s Desk Reference, 58th Edition Published by Thomson PDR Montvale NJ 07645, 2004, 2970Google Scholar
  11. Razonable R and Paya CV, Valganciclovir for the Prevention and Treatment of Cytomegalovirus Disease in Immunocompromised Hosts. Exp Rev Anti-Inf Ther 2004; 2:27–42CrossRefGoogle Scholar
  12. Rubio-Aliaga I, and Daniels H, Mammalian Peptide Transporters as Targets for Drug Delivery. Trends Pharmacol Sci 2002; 23:434–440PubMedCrossRefGoogle Scholar
  13. Sorbera LA, Castañer R, and Castañer J, Valganciclovir Hydrochloride, Drugs Future 2000; 25:474–480CrossRefGoogle Scholar
  14. Stefanidis D, and Brandl M, Reactivity of Valganciclovir in Aqueous Solution, Drug Dev Ind Pharm 2005; 31: 879–884PubMedCrossRefGoogle Scholar
  15. Sugawara M, Huang W, Fei YJ, Leibach FH, Ganapathy V, and Ganapathy ME, Transport of Valganciclovir, A Ganciclovir Prodrug, via Peptide Transporters PEPT1 and PEPT2. J Pharm Sci 2000; 89:781–789PubMedCrossRefGoogle Scholar
  16. Wan J, 1995, unpublished, personal communicationGoogle Scholar
  17. Winkler I, Winkelmann E, Scholl T, Rösner M, Jähne G and Helsberg M, Antiviral Activity and Pharmacokinetics of HOE 602, An Acyclic Nucleoside, in Animal Models. Antiviral Res 1990; 14:61–74PubMedCrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2007

Authors and Affiliations

  • Hans Maag
    • 1
  1. 1.Chemistry DepartmentRoche Palo Alto, LLCPalo AltoUSA

Personalised recommendations